U.S. Patents:

1. Use of Alpha1C Specific Compounds to Treat Benign Prostatic Hyperplasia. Gluchowski, C.; Forray, C.C.; Chiu, G.; Branchek, T.A.; Wetzel, J.M.; Hartig, P.R. (1995). U.S. Patent 5,403,847.
2. Use of Alpha-1C Specific Compounds to Treat Benign Prostatic Hyperplasia. Gluchowski, C.; Forray, C.C.; Chiu, G.; Branchek, T.A.; Wetzel, J.M.; Hartig, P.R. (1996). U.S. Patent 5,578,611.
3. Dihydropyridines and New Uses Thereof. Gluchowski, C.; Wetzel, J.M.; Chiu, G.; Marzabadi, M.R.; Wong, W.C.; Nagarathnam, D. (1998). U.S. Patent 5,767,131.
4. Use of Alpha1c Specific Compounds to Treat Benign Prostatic Hyperplasia. Gluchowski, C.; Forray, C.C.; Chiu, G.; Branchek, T.A.; Wetzel, J.M.; Hartig, P.R. (1998). U.S. Patent 5,780,485.
5. Alpha1C Specific Compounds to Treat Benign Prostatic Hyperplasia. Gluchowski, C.; Forray, C.C.; Chiu, G.; Branchek, T.A.; Wetzel; John M.; Hartig; Paul R. (1999) U.S. Patent 5,990,128.
6. Use of Alpha-1C Specific Compounds to Treat Benign Prostatic Hyperplasia. Gluchowski, C.; Forray, C.C.; Chiu, G.; Branchek, T.A.; Wetzel, J.M.; Hartig, P.R. (2000) U.S. Patent 6,015,819.
7. Dihydropyridines and New Uses Thereof. Gluchowski,C.; Wetzel, J.M.; Chiu, G.; Marzabadi, M.R.; Wong, W.C.; Nagarathnam, D. (2001) U.S. Patent 6,211,198.
8. Dihydropyridines and New Uses Thereof. Gluchowski, C.; Wetzel, J.M.; Chiu, G.; Marzabadi, M.R.; Wong, W.C.; Nagarathnam, D. (2001) U.S. Patent 6,310,076.
9. Use of Alpha1C Specific Compounds to Treat Benign Prostatic Hyperplasia. Gluchowski, C.; Forray, C.C.; Chiu; G.; Branchek, T.A.; Wetzel; J.M.; Hartig; P.R. (2003). U.S. Patent 6,602,888.
10. Dihydropyridines and New Uses Thereof. Gluchowski, C.; Wetzel; J.M.; Chiu; G.; Marzabadi, M.R.; Wong, W.C.; Nagarathnam, D. (2003). U.S. Patent 6,608,086.
11. Compounds Specific for the Human Alpha1d Adrenergic Receptor and Uses Thereof. Konkel, M.; Wetzel, J.M.; Noble, S.A.; Gluchowski, C.; Craig, D.A. (2004). U.S. Patent
6,706,716.
12. Selective Melanin Concentrating Hormone-1 (MCH1) Receptor Antagonists and Uses Thereof. Marzabadi, M.R.; Wetzel, J.; DeLeon, J.E.; Lagu, B; Gluchowski, C.; Noble, S.; Nagarathnam, D. (2004). U.S. Patent 6,720,324.
13. Substituted Anilinic Piperidines as MCH Selective Antagonists. Marzabadi, M.R.; Wetzel, J.; Deleon, J.E.; Jiang, Y.; Chen, C.-A.; Lu, K. (2004). U.S. Patent 6,727,264.
14. Substituted Anilinic Piperidines as MCH Selective Antagonists. Marzabadi, M.R.; Wetzel, J.; DeLeon, J.E.; Jiang, Y.; Chen, C.-A.; Lu, K. (2006). U.S. Patent 7,067,534.
15. Use of GALR3 Receptor Antagonists for the Treatment of Depression and/or Anxiety and Compounds Useful in Such Methods. Konkel, M.; Wetzel, J.M.; Talisman, J. (2006). U.S. Patent 7,081,470.
16. Substituted Alkyl Amido Piperidines. Marzabadi, M.R.; Wetzel, J.; Chen, C.-A.; Jiang, Y.; Lu, K. (2006). U.S. Patent 7,105,544.
17. 3-Imino-2-indolones for the Treatment of Depression and/or Anxiety. Konkel, M.; Wetzel, J.M.; Talisman, J. (2007). U.S. Patent 7,166,635.
18. Substituted Alkyl Amido Piperidines. Marzabadi,M.R.; Wetzel, J.; Chen, C.-A.; Jiang, Y.; Lu, K. (2007). U.S. Patent 7,199,135.
19. Spirocyclic Piperidines as MCH1 Antagonists and Uses Thereof. Marzabadi, M.R.; Jiang, Y.; Lu, K.; Chen, C.-A.; De Leon, J.E.; Wetzel, J.M.; Andersen, K. (2008). U.S. Patent 7,335,665.
20. Use of GALR3 Antagonist for Treatment of Depression and/or Anxiety and Compounds Useful in Such Methods. Blackburn, T.P.; Konkel, M.J.; Boteju, L.W.; Talisman, I.J.; Wetzel, J.M.; Packiarajan, M.; Chen, H.; Jimenez, H. (2008). U.S. Patent 7,465,750.
21. Secondary Amino Anilinic Piperidines as MCH1 Antagonists and Uses Thereof. Marzabadi, M.R.; Jiang, Y.; Lu, K.; Chen, C.-A.; De Leon, J.E.; Wetzel, J.M. (2009). U.S. Patent 7,473,698.

Posted in 4